Ibere Pharmaceuticals Overview
Ibere Pharmaceuticals (IBER) has a ROE of 10.08%, above the sector sector average of -4.11%.
Get informed when a big investor buys or sells
+ Follow10.08%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, IBER shows a ROE of 10.08%. That is above the sector sector average of -4.11%. Scroll down for historical charts and peer comparison views.
The its sector sector average ROE is about -4.11%. Ibere Pharmaceuticals is at 10.08%, which is higher that average. That is roughly 345.4% above the sector mean. Use the comparison chart on this page to see how IBER stacks up against individual peers as well.
Check the historical chart to see whether IBER's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Ibere Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Ibere Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 10.08%) with ownership activity and broader fundamentals.
